We are live on ! Find out more
VC

Vivo Capital Portfolio holdings

AUM $1.2B
1-Year Est. Return 911.44%
This Fund
S&P 500
This Quarter Est. Return
-15.2%
1 Year Est. Return
+911.44%
3 Year Est. Return
+7,373.93%
5 Year Est. Return
+10,475.15%
10 Year Est. Return
+136,503.27%
AUM
$783M
AUM Growth
-$209M
Cap. Flow
+$1.16M
Cap. Flow %
0.15%
Top 10 Hldgs %
67.03%
Holding
48
New
4
Increased
3
Reduced
8
Closed
3

Top Buys

Rank Stock Value
1
IOVA icon
Iovance Biotherapeutics
IOVA
+$15.4M
2
ORTX
Orchard Therapeutics plc American Depositary Shares
ORTX
+$12.1M
3
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$10M
4
DBVT
DBV Technologies
DBVT
+$4.35M
5
GLMD icon
Galmed Pharmaceuticals
GLMD
+$1.16M

Top Sells

Rank Stock Value
1
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$8.52M
2
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$8.23M
3
APLS
Apellis Pharmaceuticals
APLS
+$7.36M
4
TCDA
Tricida, Inc. Common Stock
TCDA
+$6.05M
5
SBBP
Strongbridge Biopharma plc.
SBBP
+$4.45M

Sector Composition

Rank Sector Weight
1 Healthcare 97.51%
2 Materials 2.38%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ASND icon
1
Ascendis Pharma A/S
ASND
$16.7B
$136M 17.34%
2,166,832
– –
CRNX icon
2
Crinetics Pharmaceuticals
CRNX
$8.88B
$114M 14.52%
3,792,169
– –
BHVN
3
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$67.1M 8.56%
1,813,340
-236,205
-12% -$8.52M
CDXS icon
4
Codexis
CDXS
$136M
$45.3M 5.79%
2,714,458
-34,885
-1% -$602K
SVA
5
DELISTED
Sinovac Biotech, Ltd
SVA
$40.9M 5.23%
5,900,000
– –
ARWR icon
6
Arrowhead Research
ARWR
$12.1B
$28.9M 3.69%
2,328,475
– –
KALV
7
DELISTED
KalVista Pharmaceuticals
KALV
$26.8M 3.43%
1,359,149
– –
QTTB icon
8
Q32 Bio
QTTB
$467M
$25.9M 3.31%
64,430
– –
KDMN
9
DELISTED
Kadmon Holdings, Inc.
KDMN
$21.7M 2.78%
10,454,545
– –
AMRS
10
DELISTED
Amyris Inc.
AMRS
$18.6M 2.38%
5,575,785
+667
+0% +$3.84K
TCDA
11
DELISTED
Tricida, Inc. Common Stock
TCDA
$18.4M 2.35%
781,185
-210,526
-21% -$6.05M
EIGR
12
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$18.2M 2.32%
59,709
– –
VYNE icon
13
VYNE Therapeutics
VYNE
$19.1M
$16.5M 2.11%
1,114
– –
LITS
14
Lite Strategy Inc
LITS
$33M
$15.3M 1.95%
288,905
– –
IOVA icon
15
Iovance Biotherapeutics
IOVA
$2.1B
$14.2M 1.81%
+1,600,000
New +$15.4M
VRNA
16
DELISTED
Verona Pharma
VRNA
$13.4M 1.72%
1,492,951
– –
ORTX
17
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$12.8M 1.63%
+81,189
New +$12.1M
ACRS icon
18
Aclaris Therapeutics
ACRS
$744M
$12.2M 1.55%
1,647,214
– –
OBSV
19
DELISTED
ObsEva SA Ordinary Shares
OBSV
$11.9M 1.52%
937,147
– –
ACER
20
DELISTED
Acer Therapeutics Inc
ACER
$11.7M 1.49%
579,051
+13,472
+2% +$310K
APLS
21
DELISTED
Apellis Pharmaceuticals
APLS
$11.5M 1.47%
874,573
-479,981
-35% -$7.36M
MRTX
22
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$10.7M 1.36%
+251,107
New +$10M
NBRV
23
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$9.66M 1.23%
26,477
– –
ZYME icon
24
Zymeworks
ZYME
$1.66B
$9.1M 1.16%
620,134
– –
XENE icon
25
Xenon Pharmaceuticals
XENE
$6.28B
$8.87M 1.13%
1,405,476
– –
1
2

Similar funds

SGDR
SPX Gestao de Recursos Rio De Janeiro, Brazil $1.2B AUM 59.05% 1-Year Est. Return
FCCPG
FountainVest China Capital Partners GP3 Grand Cayman, Cayman Islands $1.2B AUM 6.95% 1-Year Est. Return
GP
Guardian Partners Toronto, Canada $1.2B AUM 35.94% 1-Year Est. Return
AIM
Anchor Investment Management Columbia, South Carolina $1.2B AUM 17.33% 1-Year Est. Return
CA
Callahan Advisors Houston, Texas $1.2B AUM 22.34% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
HCM
Hodges Capital Management Dallas, Texas $1.21B AUM 49% 1-Year Est. Return
MB
MidFirst Bank Oklahoma City, Oklahoma $1.21B AUM

Vivo Capital's Q4 2018 Portfolio in Review

As of Q4 2018, Vivo Capital held 48 positions worth $783M, down 21% from $992M the previous quarter. Its ten largest holdings account for 67% of the portfolio.

Vivo Capital's Q4 2018 filing shows 4 new, 3 increased, 8 reduced and 3 closed positions. Its largest new stake was Iovance Biotherapeutics: 1,600,000 shares worth $14.2M. The largest sale was Biohaven Pharmaceutical Holding Company Ltd., an estimated $8.52M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 95% a quarter earlier, followed by Materials.

  • Vivo Capital's largest Q4 2018 buy was Iovance Biotherapeutics: 1,600,000 shares worth $14.2M.
  • Vivo Capital added most to Galmed Pharmaceuticals in Q4 2018, an estimated $1.16M increase.
  • Vivo Capital's biggest Q4 2018 reduction was Biohaven Pharmaceutical Holding Company Ltd., cutting an estimated $8.52M.
  • Vivo Capital fully exited Deciphera Pharmaceuticals, Inc. Common Stock in Q4 2018, selling an estimated $8.23M.
  • Vivo Capital's ten largest holdings make up 67% of its $783M portfolio in Q4 2018.
  • Vivo Capital opened 4 new positions and closed 3 in Q4 2018.
  • Vivo Capital's portfolio value fell 21% quarter-over-quarter to $783M.

Based on Vivo Capital's 13F filing for Q4 2018, filed 13 Feb 2019.